Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure

By sjmartinez • December 24, 2022

Talha KM, Fonarow GC, Virani SS, Butler J. Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure. Methodist Debakey Cardiovasc J. 2022 Dec 6;18(5):40-53. doi: 10.14797/mdcvj.1155. PMID: 36561085; PMCID: PMC9733124.

Tags: Cardiology/Epi, cardiovascular disease, glucagon-like peptide 1 receptor agonist, heart failure, prevention, Publications, sodium-glucose cotransporter-2 inhibitor

A rare case of May-Thurner syndrome due to external compression of the right and left common iliac veins

Schwarzman L, Aguilar J, Megowan N. A rare case of May-Thurner syndrome due to external compression of the right and left common iliac veins. J[...]

Clinical Characteristics and Current Management of U.S. Adults at Elevated Risk for Heart Failure Using the PREVENT Equations: A Cross-Sectional Analysis

Sussman JB, Wilson LM, Burke JF, Ziaeian B, Anderson TS. Clinical Characteristics and Current Management of U.S. Adults at Elevated Risk for Heart Failure Using[...]

Assessment of cardiovascular diagnoses associated with telemedicine during and after the COVID-19 pandemic

Shan R, Patel N, Chen JY, Cho D. Assessment of cardiovascular diagnoses associated with telemedicine during and after the COVID-19 pandemic. J Telemed Telecare. 2024[...]